NAFLD1
MCID: FTT008
MIFTS: 60

Fatty Liver Disease, Nonalcoholic 1 (NAFLD1)

Categories: Cancer diseases, Liver diseases, Metabolic diseases

Aliases & Classifications for Fatty Liver Disease, Nonalcoholic 1

MalaCards integrated aliases for Fatty Liver Disease, Nonalcoholic 1:

Name: Fatty Liver Disease, Nonalcoholic 1 58 30
Hepatic Steatosis 76 30 6
Fatty Liver Disease, Nonalcoholic, Susceptibility to, 1 58 13
Nafld1 58 76
Non-Alcoholic Fatty Liver Disease 1 76
Steatohepatitis 74
Fatty Liver 74

Characteristics:

OMIM:

58
Inheritance:
multifactorial

Miscellaneous:
genetic heterogeneity


HPO:

33
fatty liver disease, nonalcoholic 1:
Inheritance heterogeneous


Classifications:



External Ids:

OMIM 58 613282
MeSH 45 D005234
SNOMED-CT via HPO 70 197321007 442191002

Summaries for Fatty Liver Disease, Nonalcoholic 1

OMIM : 58 The accumulation of excess triglyceride in the liver, a condition known as hepatic steatosis (or fatty liver), is associated with adverse metabolic consequences including insulin resistance and dyslipidemia. Factors promoting deposition of fat in the liver include obesity, diabetes, insulin resistance, and alcohol ingestion. Nonalcoholic fatty liver disease (NAFLD) is the most common form of liver disease in Western countries. In a subset of individuals hepatic steatosis promotes an inflammatory response in the liver, referred to as steatohepatitis, which can progress to cirrhosis and liver cancer (summary by Romeo et al., 2008). Cohen et al. (2011) reviewed nonalcoholic fatty liver disease. (613282)

MalaCards based summary : Fatty Liver Disease, Nonalcoholic 1, also known as hepatic steatosis, is related to lipodystrophy, familial partial, type 2 and chylomicron retention disease. An important gene associated with Fatty Liver Disease, Nonalcoholic 1 is PRMT7 (Protein Arginine Methyltransferase 7), and among its related pathways/superpathways are Developmental Biology and Common Cytokine Receptor Gamma-Chain Family Signaling Pathways. The drugs Tocopherol and Entecavir have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are hepatic steatosis and growth/size/body region

UniProtKB/Swiss-Prot : 76 Non-alcoholic fatty liver disease 1: A condition characterized by accumulation of triglycerides in the liver. It is associated with adverse metabolic consequences, including insulin resistance and dyslipidemia. In a subset of individuals, hepatic steatosis promotes an inflammatory response in the liver, referred to as steatohepatitis, which can progress to cirrhosis and liver cancer. NAFLD is the most common form of liver disease in Western countries.

Related Diseases for Fatty Liver Disease, Nonalcoholic 1

Diseases in the Nonalcoholic Fatty Liver Disease family:

Fatty Liver Disease, Nonalcoholic 1 Fatty Liver Disease, Nonalcoholic 2

Diseases related to Fatty Liver Disease, Nonalcoholic 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 187)
# Related Disease Score Top Affiliating Genes
1 lipodystrophy, familial partial, type 2 32.0 INS LEP
2 chylomicron retention disease 31.7 FABP1 MTTP
3 hepatitis 31.7 GPT KRT18 SLC17A5
4 lipodystrophy, congenital generalized, type 1 31.7 ADIPOQ INS LEP
5 fatty liver disease 31.2 ADIPOQ INS LEP PPARA SLC17A5 SREBF1
6 nonalcoholic fatty liver disease 31.0 ADIPOQ INS KRT18 LEP SREBF1
7 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 30.7 ADIPOQ INS
8 hyperglycemia 30.5 ADIPOQ INS LEP
9 atherosclerosis susceptibility 30.4 ADIPOQ INS PPARA
10 viral hepatitis 30.3 GPT KRT18 SLC17A5
11 kwashiorkor 30.1 GPT SLC17A5
12 infantile liver failure syndrome 1 30.1 GPT SLC17A5
13 liver disease 30.0 ADIPOQ GPT INS KRT18 LEP PPARA
14 glucose intolerance 29.9 ADIPOQ INS LEP RETN
15 nonalcoholic steatohepatitis 29.9 ADIPOQ GPT INS KRT18 LEP SLC17A5
16 apnea, obstructive sleep 29.7 ADIPOQ INS LEP
17 sleep apnea 29.6 ADIPOQ INS LEP
18 arteries, anomalies of 29.6 ADIPOQ INS LEP
19 acanthosis nigricans 29.5 ADIPOQ INS LEP PRMT7
20 chronic kidney failure 29.4 ADIPOQ INS LEP
21 diabetes mellitus 29.1 ADIPOQ INS LEP PPARA RETN
22 lipid metabolism disorder 29.0 ADIPOQ INS LEP MTTP PPARA RETN
23 gestational diabetes 29.0 ADIPOQ INS LEP RETN
24 hypertension, essential 28.9 ADIPOQ INS LEP RETN
25 diabetes mellitus, noninsulin-dependent 28.6 ADIPOQ GPT INS LEP MTTP PPARA
26 liver cirrhosis 28.5 ADIPOQ GPT KRT18 LEP RETN SLC17A5
27 overnutrition 28.1 ADIPOQ INS LEP PPARA RETN SREBF1
28 body mass index quantitative trait locus 11 27.9 ADIPOQ GPT INS LEP MTTP PPARA
29 lipoatrophy with diabetes, hepatic steatosis, cardiomyopathy, and leukomelanodermic papules 12.3
30 hypobetalipoproteinemia, familial, 1 11.6
31 abetalipoproteinemia 11.5
32 citrullinemia, type ii, adult-onset 11.5
33 lipodystrophy, congenital generalized, type 2 11.3
34 lipodystrophy, congenital generalized, type 3 11.3
35 lipodystrophy, familial partial, type 6 11.3
36 visceral steatosis 11.3
37 lipoatrophy with diabetes, leukomelanodermic papules, liver steatosis, and hypertrophic cardiomyopathy 11.3
38 adrenomyodystrophy 11.2
39 mitochondrial trifunctional protein deficiency 11.2
40 3-methylglutaconic aciduria, type v 11.2
41 neutral lipid storage disease with myopathy 11.2
42 lipodystrophy, congenital generalized, type 4 11.2
43 lipodystrophy, familial partial, type 5 11.2
44 muscular dystrophy, limb-girdle, autosomal recessive 18 11.2
45 combined oxidative phosphorylation deficiency 16 11.2
46 combined oxidative phosphorylation deficiency 21 11.2
47 hepatitis c 10.8
48 hepatitis b 10.7
49 hepatitis c virus 10.6
50 fish-eye disease 10.6

Graphical network of the top 20 diseases related to Fatty Liver Disease, Nonalcoholic 1:



Diseases related to Fatty Liver Disease, Nonalcoholic 1

Symptoms & Phenotypes for Fatty Liver Disease, Nonalcoholic 1

Human phenotypes related to Fatty Liver Disease, Nonalcoholic 1:

33
# Description HPO Frequency HPO Source Accession
1 hepatic steatosis 33 HP:0001397

Symptoms via clinical synopsis from OMIM:

58
Abdomen Liver:
fatty liver (hepatic steatosis), nonalcoholic

Clinical features from OMIM:

613282

MGI Mouse Phenotypes related to Fatty Liver Disease, Nonalcoholic 1:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.81 ADIPOQ HADHA INS KRT18 LEP MTTP
2 homeostasis/metabolism MP:0005376 9.7 ADIPOQ FABP1 HADHA INS LEP MTTP
3 adipose tissue MP:0005375 9.65 ADIPOQ INS LEP PPARA RETN
4 liver/biliary system MP:0005370 9.36 ADIPOQ FABP1 HADHA INS KRT18 LEP

Drugs & Therapeutics for Fatty Liver Disease, Nonalcoholic 1

Drugs for Fatty Liver Disease, Nonalcoholic 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 489)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-66-2 14986
2
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
3
Milk thistle Approved, Experimental, Investigational Phase 4,Phase 2 65666-07-1
4
Ezetimibe Approved Phase 4,Phase 2 163222-33-1 150311
5
Losartan Approved Phase 4,Phase 3,Phase 2 114798-26-4 3961
6
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198
7
Simvastatin Approved Phase 4,Not Applicable 79902-63-9 54454
8
Amlodipine Approved Phase 4 88150-42-9 2162
9
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134523-00-5 60823
10
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
11
Telmisartan Approved, Investigational Phase 4,Phase 1 144701-48-4 65999
12
Liraglutide Approved Phase 4,Phase 3,Phase 2,Not Applicable 204656-20-2 44147092
13
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 32051
14
Insulin glargine Approved Phase 4,Phase 2 160337-95-1
15
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
16
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 657-24-9 14219 4091
17
Empagliflozin Approved Phase 4,Phase 3,Phase 2,Not Applicable 864070-44-0
18
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
19
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
20
Peginterferon alfa-2a Approved, Investigational Phase 4,Not Applicable 198153-51-4 5360545
21
Ribavirin Approved Phase 4,Phase 3,Not Applicable 36791-04-5 37542
22
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 111025-46-8 4829
23
Iron Approved, Experimental Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7439-89-6, 15438-31-0 27284 23925
24
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Not Applicable 122320-73-4 77999
25
Insulin Detemir Approved Phase 4 169148-63-4 5311023
26
Insulin Aspart Approved Phase 4 116094-23-6 16132418
27
Orlistat Approved, Investigational Phase 4,Phase 2 96829-58-2 3034010
28
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
29
Glucagon Approved Phase 4,Phase 2,Phase 1,Not Applicable 16941-32-5
30
tannic acid Approved Phase 4,Phase 3,Not Applicable 1401-55-4
31
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
32
Efavirenz Approved, Investigational Phase 4,Not Applicable 154598-52-4 64139
33
Gliclazide Approved Phase 4 21187-98-4 3475
34
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
35
Tamoxifen Approved Phase 4 10540-29-1 2733526
36
Rifampicin Approved Phase 4,Phase 1 13292-46-1 5381226 5458213
37
Testosterone Approved, Experimental, Investigational Phase 4,Phase 2 58-22-0, 481-30-1 10204 6013
38
Methyltestosterone Approved Phase 4,Phase 2 58-18-4 6010
39
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2 5949-44-0
40
Testosterone enanthate Approved Phase 4,Phase 2 315-37-7 9416
41
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
42
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
43
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 5754
44
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2 50-03-3
45
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
46
Racepinephrine Approved Phase 4,Phase 2 329-65-7 838
47
Toremifene Approved, Investigational Phase 4 89778-26-7 3005573
48
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
49
Rifaximin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 80621-81-4 46783403 6436173
50
Valsartan Approved, Investigational Phase 4,Phase 3 137862-53-4 60846

Interventional clinical trials:

(show top 50) (show all 1081)
# Name Status NCT ID Phase Drugs
1 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
2 Complex Imaging Assessment of Steatosis Unknown status NCT02669641 Phase 4
3 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
4 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
5 The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver Unknown status NCT01956825 Phase 4
6 Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
7 Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
8 Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients Unknown status NCT02210715 Phase 4 Isentress.
9 Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
10 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
11 Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes Unknown status NCT02303730 Phase 4 Exenatide;insulin glargine
12 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
13 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
14 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
15 Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy Unknown status NCT02652884 Phase 4 phosphate and betamethasone acetate, 2 mL.;saline 0.9% NaCl
16 The Effect of Obesity in Dexmedetomidine Metabolic Clearance Unknown status NCT02557867 Phase 4 Dexmedetomidine
17 Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease Completed NCT01006889 Phase 4 Exenatide
18 Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
19 Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
20 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
21 Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
22 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
23 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
24 Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
25 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
26 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
27 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
28 Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection Completed NCT01900015 Phase 4 Raltegravir;Efavirenz
29 Antidiabetic Effects on Intrahepatic Fat Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
30 The Effect of Vitamin D Supplementation in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
31 Liver Safety Under Upfront Arimidex vs Tamoxifen Completed NCT00537771 Phase 4 Anastrozole;Tamoxifen
32 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
33 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
34 The Effects of PXR Activation on Hepatic Fat Content Completed NCT02329405 Phase 4 Rifampicin;Placebo
35 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
36 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Diabetic Patients" (SETH2) Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
37 Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
38 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism Completed NCT02102646 Phase 4 Triptorelin
39 Pioglitazone in Hepatitis C Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
40 Use of Metformin in Treatment of Childhood Obesity Completed NCT02274948 Phase 4 Metformin;Placebo
41 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
42 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Completed NCT02733679 Phase 4 Metformin;Pioglitazone
43 Lactate Metabolism Study in HIV Infected Persons Completed NCT00202228 Phase 4 cofactor supplementation (thiamine, riboflavin, L-carnitine)
44 Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl Completed NCT00533559 Phase 4 sodium phenylbutyrate;Placebo
45 A Study of the Effects of Exercise Intensity on Insulin Sensitivity in Overweight Youth Completed NCT00755547 Phase 4
46 Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent Completed NCT02660047 Phase 4 Liraglutide;Liraglutide - Placebo
47 Adding Liraglutide to High Dose Insulin: Breaking the Cycle Completed NCT01505673 Phase 4 Liraglutide;Saline
48 Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) Completed NCT02277587 Phase 4 Plenadren;Conventional glucocorticoid therapy
49 Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer Completed NCT02344940 Phase 4 Toremifene;Tamoxifen
50 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)

Search NIH Clinical Center for Fatty Liver Disease, Nonalcoholic 1

Genetic Tests for Fatty Liver Disease, Nonalcoholic 1

Genetic tests related to Fatty Liver Disease, Nonalcoholic 1:

# Genetic test Affiliating Genes
1 Fatty Liver Disease, Nonalcoholic 1 30
2 Hepatic Steatosis 30

Anatomical Context for Fatty Liver Disease, Nonalcoholic 1

MalaCards organs/tissues related to Fatty Liver Disease, Nonalcoholic 1:

42
Liver, Testes, Kidney, Heart, Endothelial, Ovary, Bone

Publications for Fatty Liver Disease, Nonalcoholic 1

Articles related to Fatty Liver Disease, Nonalcoholic 1:

(show top 50) (show all 2234)
# Title Authors Year
1
Inhibition of PRMT3 activity reduces hepatic steatosis without altering atherosclerosis susceptibility in apoE knockout mice. ( 30776415 )
2019
2
Arazyme Suppresses Hepatic Steatosis and Steatohepatitis in Diet-Induced Non-Alcoholic Fatty Liver Disease-Like Mouse Model. ( 31083413 )
2019
3
FTY720/Fingolimod Decreases Hepatic Steatosis and Expression of Fatty Acid Synthase in Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice. ( 31110049 )
2019
4
Noninvasive monitoring of hepatic steatosis: controlled attenuation parameter and magnetic resonance imaging-proton density fat fraction in patients with nonalcoholic fatty liver disease. ( 31018719 )
2019
5
Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis. ( 30899974 )
2019
6
Human relaxin-2 attenuates hepatic steatosis and fibrosis in mice with non-alcoholic fatty liver disease. ( 30918325 )
2019
7
The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. ( 30610213 )
2019
8
Standardized Nigella sativa seed oil ameliorates hepatic steatosis, aminotransferase and lipid levels in non-alcoholic fatty liver disease: A randomized, double-blind and placebo-controlled clinical trial. ( 30639231 )
2019
9
The effects of dietary supplementation with inulin and inulin-propionate ester on hepatic steatosis in adults with non-alcoholic fatty liver disease. ( 30098126 )
2019
10
Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. ( 30178600 )
2019
11
Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis. ( 29551054 )
2019
12
Hepatic Steatosis Is Prevalent Following Orthotopic Liver Transplantation in Children With Cystic Fibrosis. ( 30234762 )
2019
13
Controlled attenuation parameter: A measure of hepatic steatosis in patients with cystic fibrosis. ( 30509601 )
2019
14
Loss of GPR109A/HCAR2 induces aging-associated hepatic steatosis. ( 30659164 )
2019
15
Oral administration of a new HRI activator as a new strategy to improve High-Fat-Diet-induced glucose intolerance, hepatic steatosis and hypertriglyceridemia through FGF21. ( 30927369 )
2019
16
Adipocyte-specific expression of a retinoic acid receptor α dominant negative form causes glucose intolerance and hepatic steatosis in mice. ( 31109648 )
2019
17
Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis. ( 31094016 )
2019
18
Novel predictive models using serum ceruloplasmin levels for hepatic steatosis in patients with chronic hepatitis B infection. ( 31076363 )
2019
19
Therapy with Oral Directly Acting Agents in Hepatitis C Infection Is Associated with Reduction in Fibrosis and Increase in Hepatic Steatosis on Transient Elastography. ( 31024203 )
2019
20
Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue. ( 30912255 )
2019
21
Elevated serum ferritin level associated with hepatic steatosis and fibrosis in hepatitis C virus-infected patients. ( 30839498 )
2019
22
How does hepatic steatosis affect the outcome of patients with chronic hepatitis B? ( 30661335 )
2019
23
Comparison of Acoustic Structure Quantification, Transient Elastography (FibroScan) and Histology in Patients with Chronic Hepatitis B and without Moderate to Severe Hepatic Steatosis. ( 30638967 )
2019
24
Can hepatic steatosis really promote hepatitis B viral hepatocarcinogenesis? The jury is out on. ( 30599476 )
2019
25
Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B. ( 30360031 )
2019
26
Development of Hepatic Steatosis After Chemotherapy for Non-Hodgkin Lymphoma. ( 30766960 )
2019
27
D-Chiro-inositol Ameliorates High Fat Diet-Induced Hepatic Steatosis and Insulin Resistance via PKCε-PI3K/AKT Pathway. ( 31066268 )
2019
28
Honokiol Improves Insulin Resistance, Hepatic Steatosis, and Inflammation in Type 2 Diabetic db/db Mice. ( 31075962 )
2019
29
Dietary Eriodictyol Alleviates Adiposity, Hepatic Steatosis, Insulin Resistance, and Inflammation in Diet-Induced Obese Mice. ( 30862092 )
2019
30
Global Tudor-SN transgenic mice are protected from obesity-induced hepatic steatosis and insulin resistance. ( 30521378 )
2019
31
Quinoa intake reduces plasma and liver cholesterol, lessens obesity-associated inflammation, and helps to prevent hepatic steatosis in obese db/db mouse. ( 30857678 )
2019
32
Electrophilic nitro-oleic acid reverses obesity-induced hepatic steatosis. ( 30769284 )
2019
33
Inhibition of soluble epoxide hydrolase ameliorates hyperhomocysteinemia-induced hepatic steatosis by enhancing β-oxidation of fatty acid in mice. ( 30789748 )
2019
34
Orphan nuclear receptor NR4A1 suppresses hyperhomocysteinemia-induced hepatic steatosis in vitro and in vivo. ( 30973961 )
2019
35
Utility of Attenuation Coefficient Measurement Using an Ultrasound-Guided Attenuation Parameter for Evaluation of Hepatic Steatosis: Comparison With MRI-Determined Proton Density Fat Fraction. ( 30476453 )
2019
36
Combination of Whole Grapeseed Flour and Newly Isolated Kefir Lactic Acid Bacteria Reduces High-Fat-Induced Hepatic Steatosis. ( 30537110 )
2019
37
IL-25 protects against high-fat diet-induced hepatic steatosis in mice by inducing IL-25 and M2a macrophage production. ( 30242904 )
2019
38
A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. ( 30389552 )
2019
39
Perilipin 5 promotes hepatic steatosis in dairy cows through increasing lipid synthesis and decreasing very low density lipoprotein assembly. ( 30415861 )
2019
40
6-gingerol ameliorates age-related hepatic steatosis: Association with regulating lipogenesis, fatty acid oxidation, oxidative stress and mitochondrial dysfunction. ( 30408433 )
2019
41
Roles of extrahepatic lipolysis and the disturbance of hepatic fatty acid metabolism in TNF-α -induced hepatic steatosis. ( 30359672 )
2019
42
Clinical significance of hepatic steatosis according to coronary plaque morphology: assessment using controlled attenuation parameter. ( 30284617 )
2019
43
Trivalent Chromium Supplementation Ameliorates Oleic Acid-Induced Hepatic Steatosis in Mice. ( 29797206 )
2019
44
Tangshen Formula Alleviates Hepatic Steatosis by Inducing Autophagy Through the AMPK/SIRT1 Pathway. ( 31105592 )
2019
45
A critical appraisal of the use of ultrasound in hepatic steatosis. ( 31104523 )
2019
46
Xiaochaihu Decoction reduces hepatic steatosis and improves D-GalN/LPS-induced liver injury in hybrid grouper (Epinephelus lanceolatus♂ × Epinephelus fuscoguttatus♀). ( 31100441 )
2019
47
Bone Morphogenetic Protein-8B Expression is Induced in Steatotic Hepatocytes and Promotes Hepatic Steatosis and Inflammation In Vitro. ( 31096638 )
2019
48
Contamination of organohalogen chemicals and hepatic steatosis in common kingfisher (Alcedo atthis) breeding at a nature reserve near e-waste recycling sites in South China. ( 31096385 )
2019
49
Feasibility of non-enhanced CT for assessing longitudinal changes in hepatic steatosis. ( 31083253 )
2019
50
Design, Synthesis, and Pre-Clinical Efficacy of Novel Non-Retinoid Antagonists of Retinol Binding Protein 4 in the Mouse Model of Hepatic Steatosis. ( 31079449 )
2019

Variations for Fatty Liver Disease, Nonalcoholic 1

ClinVar genetic disease variations for Fatty Liver Disease, Nonalcoholic 1:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 OPA1 NM_130837.2(OPA1): c.113_130delGAAGCATTTATCATTCAC (p.Arg38_Ser43del) deletion Conflicting interpretations of pathogenicity rs863224140 GRCh38 Chromosome 3, 193614803: 193614820
2 OPA1 NM_130837.2(OPA1): c.113_130delGAAGCATTTATCATTCAC (p.Arg38_Ser43del) deletion Conflicting interpretations of pathogenicity rs863224140 GRCh37 Chromosome 3, 193332592: 193332609
3 MT-TL1 NC_012920.1: m.3275C> T single nucleotide variant Uncertain significance rs1057516057 GRCh37 Chromosome MT, 3275: 3275
4 MT-TL1 NC_012920.1: m.3275C> T single nucleotide variant Uncertain significance rs1057516057 GRCh38 Chromosome MT, 3275: 3275
5 PRMT7 NM_001290018.1(PRMT7): c.322G> T (p.Glu108Ter) single nucleotide variant Pathogenic/Likely pathogenic rs1014959895 GRCh37 Chromosome 16, 68363008: 68363008
6 PRMT7 NM_001290018.1(PRMT7): c.322G> T (p.Glu108Ter) single nucleotide variant Pathogenic/Likely pathogenic rs1014959895 GRCh38 Chromosome 16, 68329105: 68329105
7 PRMT7 NM_001290018.1(PRMT7): c.1713C> A (p.Cys571Ter) single nucleotide variant Pathogenic rs1251713297 GRCh37 Chromosome 16, 68389688: 68389688
8 PRMT7 NM_001290018.1(PRMT7): c.1713C> A (p.Cys571Ter) single nucleotide variant Pathogenic rs1251713297 GRCh38 Chromosome 16, 68355785: 68355785

Expression for Fatty Liver Disease, Nonalcoholic 1

Search GEO for disease gene expression data for Fatty Liver Disease, Nonalcoholic 1.

Pathways for Fatty Liver Disease, Nonalcoholic 1

Pathways related to Fatty Liver Disease, Nonalcoholic 1 according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.24 ADIPOQ INS KRT18 LEP PPARA SREBF1
2
Show member pathways
12.51 ADIPOQ INS LEP RETN
3
Show member pathways
12.41 ADIPOQ FABP1 HADHA LEP PPARA SREBF1
4 12.2 ADIPOQ FABP1 INS SREBF1
5
Show member pathways
12.08 ADIPOQ INS LEP SREBF1
7
Show member pathways
11.65 INS PPARA SREBF1
8 11.37 ADIPOQ FABP1 PPARA
9 11.27 ADIPOQ LEP PPARA
10 11.22 ADIPOQ INS LEP PPARA RETN SREBF1
11 10.94 FABP1 PPARA
12 10.91 ADIPOQ LEP
13 10.84 ADIPOQ LEP
14 10.76 PPARA SREBF1
15 10.66 GPT INS

GO Terms for Fatty Liver Disease, Nonalcoholic 1

Biological processes related to Fatty Liver Disease, Nonalcoholic 1 according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.88 ADIPOQ INS LEP RETN
2 response to hypoxia GO:0001666 9.76 ADIPOQ LEP PPARA
3 lipid metabolic process GO:0006629 9.72 HADHA LEP MTTP PPARA SREBF1
4 glucose homeostasis GO:0042593 9.69 ADIPOQ INS LEP
5 positive regulation of glucose import GO:0046326 9.6 ADIPOQ INS
6 negative regulation of blood pressure GO:0045776 9.59 ADIPOQ PPARA
7 lipoprotein metabolic process GO:0042157 9.57 MTTP PPARA
8 response to lipid GO:0033993 9.56 PPARA SREBF1
9 positive regulation of cellular protein metabolic process GO:0032270 9.55 ADIPOQ INS
10 positive regulation of insulin receptor signaling pathway GO:0046628 9.54 INS LEP
11 negative regulation of gluconeogenesis GO:0045721 9.52 ADIPOQ INS
12 intestinal absorption GO:0050892 9.49 FABP1 LEP
13 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.48 ADIPOQ PPARA
14 positive regulation of fatty acid beta-oxidation GO:0032000 9.46 FABP1 PPARA
15 negative regulation of appetite GO:0032099 9.43 LEP PPARA
16 glucose metabolic process GO:0006006 9.43 ADIPOQ INS LEP
17 negative regulation of feeding behavior GO:2000252 9.4 INS RETN
18 regulation of fatty acid metabolic process GO:0019217 9.37 PPARA SREBF1
19 fatty acid beta-oxidation GO:0006635 9.33 ADIPOQ HADHA LEP
20 circadian rhythm GO:0007623 9.26 ADIPOQ LEP MTTP SREBF1
21 response to insulin GO:0032868 8.92 HADHA LEP PPARA RETN

Molecular functions related to Fatty Liver Disease, Nonalcoholic 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fatty acid binding GO:0005504 8.96 FABP1 PPARA
2 hormone activity GO:0005179 8.92 ADIPOQ INS LEP RETN

Sources for Fatty Liver Disease, Nonalcoholic 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....